Transcriptional Regulation of Matrix Metalloproteinases

Extracellular Matrix and The Liver: Approach to Gene Therapy

Volumn , Issue , 2003, Pages 277-297

  Benbow, Ulrike ^a,b   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866405106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012525251-5/50016-6     Document Type: Chapter

References (98)

1. Aho S., Rouda S., Kennedy S.H., Qin H., Tan E.M. Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor. Eur. J. Biochem. 1997, 247:503-510.
2. Barchowsky A., Frleta D., Vincenti M.P. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: Divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000, 12:1469-1479.
3. Basset P., Okada A., Chenard M.P., Kannan R., Stoll I., Anglard P., Bellocq J.P., Rio M.C. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol. 1997, 15:535-541.
4. Benbow U., Brinckerhoff C.E. The AP-1 site and MMP gene regulation: What is all the fuss about?. Matrix Biol. 1997, 15:519-526.
5. Benbow U., Schoenermark M.P., Mitchell T.I., Rutter J.L., Shimokawa K., Nagase H., Brinckerhoff C.E. A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J. Biol. Chem. 1999, 274:25371-25378.
6. Benbow U., Schoenermark M.P., Orndorff K.A., Givan A.L., Brinckerhoff C.E. Human breast cancer cells activate procollagenase-1 and invade type I collagen: Invasion is inhibited by all-trans retinoic acid. Clin. Exp. Metast. 1999, 17:231-238.
7. Borden P., Solymar D., Sucharczuk A., Lindman B., Cannon P., Heller R.A. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J. Biol. Chem. 1996, 271:23577-23581.
8. Borden P., Heller R.A. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit. Rev. Eukaryot. Gene Expr. 1997, 7:159-178.
9. Boulay A., Masson R., Chenard M.P., El Fahime M., Cassard L., Bellocq J.P., Sautes-Fridman C., Basset P., Rio M.C. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 2001, 61:2189-2193.
10. Brauchle M., Gluck D., Di Padova F., Han J., Gram H. Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1. Exp. Cell Res. 2000, 258:135-144.
11. Brinckerhoff C.E., Rutter J.L., Benbow U. Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 2000, 6:4823-4830.
12. Buolamwini K.K. Novel anticancer drug discovery. Curr. Opin. Chem. Biol. 1999, 3:500-509.
13. Buttice G., Kurkinen M. A polyomavirus enhancer A-binding protein-3 site and Ets-2 protein have a major role in the 12-O-tetradecanoylphorbol-13-acetate response of the human stromelysin gene. J. Biol. Chem. 1993, 268:7196-7204.
14. Chamberlain S.H., Hemmer R.M., Brinckerhoff C.E. Novel phorbol ester response region in the collagenase promoter binds Fos and Jun. J. Cell Biochem. 1993, 52:337-351.
15. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 1997, 89:1260-1270.
16. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189:300-308.
17. de Maat M.P., Jukema J.W., Ye S., Zwinderman A.H., Moghaddam P.H., Beekman M., Kastelein J.J., van Boven A.J., Bruschke A.V., Humphries S.E., Kluft C., Henney A.M. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am. J. Cardiol. 1999, 83:852-856.
18. Deng T., Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev. 1993, 7:479-490.
19. Durko M., Navab R., Shibata H.R., Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim. Biophys. Acta 1997, 1356:271-280.
20. Engsig M.T., Chen Q.J., Vu T.H., Pedersen A.C., Therkidsen B., Lund L.R., Henriksen K., Lenhard T., Foged N.T., Werb Z., Delaisse J.M. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J. Cell Biol. 2000, 151:879-890.
21. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
22. Greenwald R.A., Zucker S., Golub L.M. Inhibition of matrix metalloproteinases: Therapeutic application. Ann. N. Y. Acad. Sci. 2000, 878.
23. Heimbrook D.C., Oliff A. Therapeutic intervention and signaling. Curr. Opin. Cell Biol. 1998, 10:284-288.
24. Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA 1991, 88:8154-8158.
25. Herbst R.A., Gutzmer R., Matiaske F., Mommert S., Casper U., Kapp A., Weiss J. Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma. Int. J. Cancer 1999, 80:205-209.
26. Herbst R.A., Mommert S., Casper U., Podewski E.K., Kiehl P., Kapp A., Weiss J. 11q23 allelic loss is associated with regional lymph node metastasis in melanoma. Clin. Cancer Res. 2000, 6:3222-3227.
27. Holmbeck K., Bianco P., Caterina J., Yamada S., Kromer M., Kuznetsov S.A., Mankani M., Robey P.G., Poole A.R., Pidoux I., Ward J.M., Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
28. Hotary K., Allen E., Puntuieri A., Yana I., Weiss S.J. Regulation of cell invasion and morphogenesis in a three dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 2000, 149:1309-1323.
29. Humphries S.E., Luong L.A., Talmud P.J., Frick M.H., Kesaniemi Y.A., Pasternack A., Taskinen M.R., Syvanne M. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study: Lipid Coronary Angiography Trial. Atherosclerosis 1998, 139:49-56.
30. Inoue T., Yashiro M., Nishimura S., Maeda K., Sawada T., Ogawa Y., Sowa M., Chung K.H. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int. J. Mol. Med. 1999, 4:73-77.
31. Ito T., Ito M., Shiozawa J., Naito S., Kanematsu T., Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor. Mod. Pathol. 1999, 12:669-674.
32. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
33. Jimenez M.J., Balbin M., Lopez J.M., Alvarez J., Komori T., Lopez-Otin C. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell Biol. 1999, 19:4431-4442.
34. Johansson N., Vaalamo M., Grenman S., Hietanen S., Klemi P., Saarialho-Kere U., Kahari V.M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am. J. Pathol. 1999, 154:469-480.
35. Jormsjo S., Ye S., Moritz J., Walter D.H., Dimmeler S., Zeiher A.M., Henney A., Hamsten A., Eriksson P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res. 2000, 86:998-1003.
36. Kahari V.M., Johansson N., Grenman R., Airola K., Saarialho-Kere U. Expression of collagenase-3 (MMP-13) by tumor cells in squamous cell carcinomas of the head and neck. Adv. Exp. Med. Biol. 1998, 451:63-68.
37. Kanamori Y., Matsushima M., Minaguchi T., Kobayashi K., Sagae S., Kudo R., Terakawa N., Nakamura Y. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999, 59:4225-4227.
38. Kerr L.D., Miller D.B., Matrisian L.M. TGF-beta 1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 1990, 61:267-278.
39. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291:113-135.
40. Kramer I.M., Koornneef I., de Laat S.W., van den Eijnden-van Raaij A.J. TGF-beta 1 induces phosphorylation of the cyclic AMP responsive element binding protein in ML-CCl64 cells. EMBO J. 1991, 10:1083-1089.
41. Lohi J., Lehti K., Valtanen H., Parks W.C., Keski-Oja J. Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000, 242:75-86.
42. Masson R., Lefebvre O., Noel A., Fahime M.E., Chenard M.P., Wendling C., Kebers F., LeMeur M., Dierich A., Foidart J.M., Basset P., Rio M.C. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 1998, 140:1535-1541.
43. Mauviel A., Chung K.Y., Agarwal A., Tamai K., Uitto J. Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J. Biol. Chem. 1996, 271:10917-10923.
44. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol. Med. Today 2000, 6:149-156.
45. Mengshol J.A., Vincenti M.P., Brinckerhoff C.E. Transcriptional regulation of collagenase-3 (MMP-13) by IL-1 chondrocytic cells requires stable chromatin integration and the transcription factors Runx-2 and AP-1. Nucleic Acid Res. 2001, 29:4361-4372.
46. Mengshol J.A., Vincenti M.P., Coon C.I., Barchowsky A., Brinckerhoff C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43:801-811.
47. Mengshol J.M., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases as therapeutic targets in arthritic diseases: Bull's eye or missing the mark?. Arthritis Rheum 2002, 46:13-20.
48. Mudgett J.S., Hutchinson N.I., Chartrain N.A., Forsyth A.J., McDonnell J., Singer I., Bayne E.K., Flanagan J., Kawka D., Shen C.F., Stevens K., Chen H., Trumbauer M., Visco D.M. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998, 41:110-121.
49. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 1996, 2:461-462.
50. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 1998, 185:256-261.
51. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 1999, 274:21491-21494.
52. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 2000, 18:1135-1149.
53. Neuhold L.A., Killar L., Zhao W., Sung M.L., Warner L., Kulik J., Turner J., Wu W., Billinghurst C., Meijers T., Poole A.R., Babij P., DeGennaro L.J. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J. Clin. Invest. 2001, 107:35-44.
54. Nishioka Y., Kobayashi K., Sagae S., Ishioka S., Nishikawa A., Matsushima M., Kanamori Y., Minaguchi T., Nakamura Y., Tokino T., Kudo R. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn. J. Cancer Res. 2000, 91:612-615.
55. Noll W.W., Belloni D.R., Rutter J.L., Storm C.A., Schned A.R., Titus-Ernstoff L., Ernstoff M.S., Brinckerhoff C.E. Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am. J. Pathol. 2001, 158:691-697.
56. Ohuchi E., Imai K., Fuji Y., Sato H., Seiki M., Okada Y. Membrane type I matrix metalloproteinase digests interstitial collagenase and other extracellular matrix macromolecules. J. Biol. Chem. 1997, 272:2446-2451.
57. Parsons S.L., Watson S.A., Brown P.D., Collins H.M., Steele R.J. Matrix metalloproteinases. Br. J. Surg. 1997, 84:160-166.
58. Pei D. Identificaton and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J. Biol. Chem. 1999, 274:8925-8933.
59. Peters D.G., Kassam A., St Jean P.L., Yonas H., Ferrell R.E. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999, 30:2612-2616.
60. Porte D., Tuckermann J., Becker M., Baumann B., Teurich S., Higgins T., Owen M.J., Schorpp-Kistner M., Angel P. Both AP-1 and Cbfal-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 1999, 18:667-678.
61. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J. Clin. Oncol. 1999, 17:3631-3652.
62. Rutter J.L., Benbow U., Coon C.I., Brinckerhoff C.E. Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells. J. Cell Biochem. 1997, 66:322-336.
63. Rutter J.L., Mitchell T.I., Buttice G., Meyers J., Gusella J.F., Ozelius L.J., Brinckerhoff C.E. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998, 58:5321-5325.
64. Sato H., Kita M., Seiki M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements: A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 1993, 268:23460-23468.
65. Sato H., Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993, 8:395-405.
66. Schadendorf D., Kern M.A., Artuc M., Pahl H.L., Rosenbach T., Fichtner I., Nurnberg W., Stuting S., von Stebut E., Worm M., Makki A., Jurgovsky K., Kolde G., Henz B.M. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J. Cell Biol. 1996, 135:1889-1898.
67. Schoenermark M.P., Mitchell T.I., Rutter J.L., Reczek P.R., Brinckerhoff C.E. Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis. Ann. N. Y. Acad. Sci. 1999, 878:466-486.
68. Schroen D.J., Chen J.D., Vincenti M.P., Brinckerhoff C.E. The nuclear receptor corepressor SMRT inhibits interstitial collagenase (MMP-1) transcription through an HRE-independent mechanism. Biochem. Biophys. Res. Commun. 1997, 237:52-58.
69. Sherry S.T., Ward M., Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 1999, 9:677-679.
70. Shimajiri S., Arima N., Tanimoto A., Murata Y., Hamada T., Wang K.Y., Sasaguri Y. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999, 455:70-74.
71. Shlopov B.V., Lie W.R., Mainardi C.L., Cole A.A., Chubinskaya S., Hasty K.A. Osteoarthritic lesions: Involvement of three different collagenases. Arthritis Rheum 1997, 40:2065-2074.
72. Singh H., Sekinger E.A., Gross D.S. Chromatin and cancer: Causes and consequences. J. Cell Biochem. 2000, 61-68. Suppl.
73. Spanjaard R.A., Ikeda M., Lee P.J., Charpentier B., Chin W.W., Eberlein T.J. Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells. J. Biol. Chem. 1997, 272:18990-18999.
74. Sporn M.B., Roberts A.B., Goodman D.S. The Retinoids 1994, Raven Press, Austin, TX.
75. Terashima M., Akita H., Kanazawa K., Inoue N., Yamada S., Ito K., Matsuda Y., Takai E., Iwai C., Kurogane H., Yoshida Y., Yokoyama M. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999, 99:2717-2719.
76. Tower G.B., Benbow U., Brinckerhoff C.E. ERK1/2 differentially regulates the expression from 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochim. Biophys. Acta 2002, 1586:265-274.
77. Tsukifuji R., Tagawa K., Hatamochi A., Shinkai H. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis. Br. J. Cancer 1999, 80:1087-1091.
78. Uitto V.J., Airola K., Vaalamo M., Johansson N., Putnins E.E., Firth J.D., Salonen J., Lopez-Otin C., Saarialho-Kere U., Kahari V.M. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am. J. Pathol. 1998, 152:1489-1499.
79. Velasco G., Cal S., Merlos-Suarez A., Ferrando A.A., Alvarez S., Nakano A., Arribas J., Lopez-Otin C. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000, 60:877-882.
80. Vincenti M.P., Clark I.M., Brinckerhoff C.E. Using inhibitors of metalloproteinases to treat arthritis: Easier said than done. Arthritis Rheum 1994, 37:1115-1126.
81. Vincenti M.P., Coon C.I., Brinckerhoff C.E. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1 beta-stimulated synovial fibroblasts. Arthritis Rheum. 1998, 41:1987-1994.
82. Vincenti M.P., White L.A., Schroen D.J., Benbow U., Brinckerhoff C.E. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): Mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot. Gene Expr. 1996, 6:391-411.
83. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
84. Wasylyk B., Wasylyk C., Flores P., Begue A., Leprince D., Stehelin D. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature 1990, 346:191-193.
85. Wasylyk C., Gutman A., Nicholson R., Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J. 1991, 10:1127-1134.
86. Westermarck J., Holmstrom T., Ahonen M., Eriksson J.E., Kahari V.M. Matrix Biol. 1998, 17:547-557.
87. Westermark J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 291:113-135.
88. Westermarck J., Li S., Jaakkola P., Kallunki T., Grenman R., Kahari V.M. Activation of fibroblast collagenase-1 expression by tumor cells of squamous cell carcinomas is mediated by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase-2. Cancer Res. 2000, 60:7156-7162.
89. White L.A., Brinckerhoff C.E. Two activator protein-1 elements in the matrix metalloproteinase-1 promoter have different effects on transcription and bind Jun D, c-Fos, and Fra-2. Matrix Biol. 1995, 14:715-725.
90. White L.A., Mitchell T.I., Brinckerhoff C.E. Transforming growth factor beta inhibitory element in the rabbit matrix metalloproteinase-1 (collagenase-1) gene functions as a repressor of constitutive transcription. Biochim. Biophys. Acta 2000, 1490:259-268.
91. Ye S., Dhillon S., Turner S.J., Bateman A.C., Theaker J.M., Pickering R.M., Day I., Howell W.M. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 2001, 61:1296-1298.
92. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996, 271:13055-13060.
93. Ye S., Humphries S., Henney A. Matrix metalloproteinases: Implication in vascular matrix remodelling during atherogenesis. Clin. Sci. (Colch) 1998, 94:103-110.
94. Yoon S., Tromp G., Vongpunsawad S., Ronkainen A., Juvonen T., Kuivaniemi H. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem. Biophys. Res. Commun. 1999, 265:563-568.
95. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., Arveiler D., Luc G., Cambien F., Hamsten A., Watkins H., Henney A.M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
96. Zhou Z., Apte S.S., Soininen R., Cao R., Baaklini G.Y., Rauser R.W., Wang J., Cao Y., Tryggvason K. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA 2000, 97:4052-4057.
97. Zhu Y., Spitz M.R., Wu X. A single nucleotide polymorphism in the matrix metalloproteinase 1 (MMP-1) promoter enhances lung cancer susceptibility. Cancer Res. 2001, 61:7825-7829.
98. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19:6642-6650.